primaquine has been researched along with Adverse Drug Event in 16 studies
Primaquine: An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Adverse effects include anemias and GI disturbances. (From Martindale, The Extra Pharmacopeia, 30th ed, p404)
primaquine : An N-substituted diamine that is pentane-1,4-diamine substituted by a 6-methoxyquinolin-8-yl group at the N(4) position. It is a drug used in the treatment of malaria and Pneumocystis pneumonia.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study assessed the safety of the new World Health Organization (WHO) recommendation of adding a single low-dose of primaquine (PQ) to standard artemisinin-based combination therapy (ACT), regardless of individual glucose-6-phosphate dehydrogenase (G6PD) status, for treatment of acute uncomplicated Plasmodium falciparum malaria in Tanzania." | 9.22 | Safety of a single low-dose of primaquine in addition to standard artemether-lumefantrine regimen for treatment of acute uncomplicated Plasmodium falciparum malaria in Tanzania. ( Björkman, A; Gosling, R; Jovel, I; Mårtensson, A; Mmbando, BP; Mwaiswelo, R; Ngasala, BE; Poirot, E; Premji, Z, 2016) |
| "This study assessed the safety of the new World Health Organization (WHO) recommendation of adding a single low-dose of primaquine (PQ) to standard artemisinin-based combination therapy (ACT), regardless of individual glucose-6-phosphate dehydrogenase (G6PD) status, for treatment of acute uncomplicated Plasmodium falciparum malaria in Tanzania." | 5.22 | Safety of a single low-dose of primaquine in addition to standard artemether-lumefantrine regimen for treatment of acute uncomplicated Plasmodium falciparum malaria in Tanzania. ( Björkman, A; Gosling, R; Jovel, I; Mårtensson, A; Mmbando, BP; Mwaiswelo, R; Ngasala, BE; Poirot, E; Premji, Z, 2016) |
| "Glucose-6-phosphate dehydrogenase deficiency (G6PD), an x-linked inherited enzymopathy, is a barrier to malaria control because primaquine cannot be readily applied for radical cure in individuals with the condition." | 3.79 | Prevalence and molecular basis of glucose-6-phosphate dehydrogenase deficiency in Afghan populations: implications for treatment policy in the region. ( Amanzai, O; Beg, MA; Jan, S; Leslie, T; Mohammad, N; Moiz, B; Nasir, A; Siddiqi, AM; Ur Rasheed, H; Vink, M, 2013) |
| "Primaquine regimens were categorized according to the total dose administered: very low (≤2." | 2.48 | Primaquine radical cure of Plasmodium vivax: a critical review of the literature. ( Baird, JK; Douglas, NM; John, GK; Nosten, F; Price, RN; von Seidlein, L; White, NJ, 2012) |
| "The Primaquine Roll Out Monitoring Pharmacovigilance Tool (PROMPT), comprising: (1) a standardized form to support the surveillance of possible adverse events following SLD PQ treatment; (2) a patient information card to enhance awareness of known adverse drug reactions of SLD PQ use; and (3) a database compiling recorded information, was developed and piloted." | 1.43 | Development of a pharmacovigilance safety monitoring tool for the rollout of single low-dose primaquine and artemether-lumefantrine to treat Plasmodium falciparum infections in Swaziland: a pilot study. ( Brown, J; Darteh, S; Gosling, R; Hwang, J; Kunene, S; Malambe, C; Maphalala, G; Mkhonta, N; Mwandemele, A; Ntshalintshali, N; Pace, C; Pan, S; Poirot, E; Soble, A; Stergachis, A; Vilakati, S; Vittinghoff, E, 2016) |
| " We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts." | 1.37 | FDA-approved drug labeling for the study of drug-induced liver injury. ( Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (31.25) | 18.7374 |
| 1990's | 1 (6.25) | 18.2507 |
| 2000's | 1 (6.25) | 29.6817 |
| 2010's | 8 (50.00) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M | 1 |
| Vijay, V | 1 |
| Shi, Q | 2 |
| Liu, Z | 2 |
| Fang, H | 2 |
| Tong, W | 2 |
| Ding, D | 1 |
| Kelly, R | 1 |
| Morgan, RE | 1 |
| van Staden, CJ | 1 |
| Chen, Y | 1 |
| Kalyanaraman, N | 1 |
| Kalanzi, J | 1 |
| Dunn, RT | 1 |
| Afshari, CA | 1 |
| Hamadeh, HK | 1 |
| Saita, S | 1 |
| Roobsoong, W | 1 |
| Khammaneechan, P | 1 |
| Sukchan, P | 1 |
| Lawpoolsri, S | 1 |
| Sattabongkot, J | 1 |
| Cui, L | 1 |
| Okanurak, K | 1 |
| Phuanukoonnon, S | 1 |
| Parker, DM | 1 |
| Leslie, T | 1 |
| Moiz, B | 1 |
| Mohammad, N | 1 |
| Amanzai, O | 1 |
| Ur Rasheed, H | 1 |
| Jan, S | 1 |
| Siddiqi, AM | 1 |
| Nasir, A | 1 |
| Beg, MA | 1 |
| Vink, M | 1 |
| Mwaiswelo, R | 1 |
| Ngasala, BE | 1 |
| Jovel, I | 1 |
| Gosling, R | 2 |
| Premji, Z | 1 |
| Poirot, E | 2 |
| Mmbando, BP | 1 |
| Björkman, A | 1 |
| Mårtensson, A | 1 |
| Soble, A | 1 |
| Ntshalintshali, N | 1 |
| Mwandemele, A | 1 |
| Mkhonta, N | 1 |
| Malambe, C | 1 |
| Vilakati, S | 1 |
| Pan, S | 1 |
| Darteh, S | 1 |
| Maphalala, G | 1 |
| Brown, J | 1 |
| Hwang, J | 1 |
| Pace, C | 1 |
| Stergachis, A | 1 |
| Vittinghoff, E | 1 |
| Kunene, S | 1 |
| Drew, L | 1 |
| John, GK | 1 |
| Douglas, NM | 1 |
| von Seidlein, L | 1 |
| Nosten, F | 1 |
| Baird, JK | 1 |
| White, NJ | 1 |
| Price, RN | 1 |
| Gogtay, NJ | 1 |
| Kamtekar, KD | 1 |
| Dalvi, SS | 1 |
| Mehta, SS | 1 |
| Chogle, AR | 1 |
| Aigal, U | 1 |
| Kshirsagar, NA | 1 |
| Gervais, P | 1 |
| Diamant-Berger, O | 1 |
| Tingle, MD | 1 |
| Park, BK | 1 |
| Smuckler, EA | 1 |
| Waller, HD | 1 |
| Waser, PG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy and Safety of a Single Low-dose Primaquine Added to Standard Artemether-lumefantrine Treatment for the Clearance of Plasmodium Falciparum Gametocytes.[NCT02090036] | Phase 4 | 220 participants (Actual) | Interventional | 2014-07-31 | Completed | ||
| "Aiming at Prolonging the Therapeutic Life Span of Artemisinin-based Combination Therapies (ACT) in an Era of Imminent Plasmodium Falciparum Resistance in Bagamoyo District, Tanzania - New Strategies With Old Tools"[NCT03241901] | Phase 4 | 280 participants (Actual) | Interventional | 2017-07-27 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for primaquine and Adverse Drug Event
| Article | Year |
|---|---|
Primaquine radical cure of Plasmodium vivax: a critical review of the literature.
Topics: Antimalarials; Clinical Trials as Topic; Drug-Related Side Effects and Adverse Reactions; Humans; Ma | 2012 |
Iatrogenic disease, drug metabolism, and cell injury: lethal synthesis in man.
Topics: Biotransformation; Cell Survival; Chloroform; Diet; Drug-Related Side Effects and Adverse Reactions; | 1977 |
[Adverse effects of drugs in hereditary variants in the enzyme apparatus of the body].
Topics: Adenosine Triphosphatases; Adult; Aged; Cholinesterase Inhibitors; Coumarins; Dibucaine; Drug-Relate | 1968 |
2 trials available for primaquine and Adverse Drug Event
11 other studies available for primaquine and Adverse Drug Event
| Article | Year |
|---|---|
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Des | 2011 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Da | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily | 2013 |
Community acceptability, participation, and adherence to mass drug administration with primaquine for Plasmodium vivax elimination in Southern Thailand: a mixed methods approach.
Topics: Antimalarials; Cross-Sectional Studies; Drug-Related Side Effects and Adverse Reactions; Female; Hum | 2023 |
Prevalence and molecular basis of glucose-6-phosphate dehydrogenase deficiency in Afghan populations: implications for treatment policy in the region.
Topics: Adolescent; Afghanistan; Animals; Antimalarials; Child; Child, Preschool; Cross-Sectional Studies; D | 2013 |
Development of a pharmacovigilance safety monitoring tool for the rollout of single low-dose primaquine and artemether-lumefantrine to treat Plasmodium falciparum infections in Swaziland: a pilot study.
Topics: Adolescent; Adult; Aged; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Chi | 2016 |
Pharmacogenetics: The right drug for you.
Topics: Antidepressive Agents; Child; Dideoxynucleosides; Drug Hypersensitivity; Drug-Related Side Effects a | 2016 |
[Adverse effects of drugs: errors or risk?].
Topics: Drug-Related Side Effects and Adverse Reactions; Humans; Infant, Newborn; Pharmaceutical Preparation | 1982 |
The use of a three compartment in vitro model to investigate the role of hepatic drug metabolism in drug-induced blood dyscrasias.
Topics: Animals; Dapsone; Drug-Related Side Effects and Adverse Reactions; Erythrocyte Count; Hematologic Di | 1993 |
[Pharmacogenetics].
Topics: Anemia, Hemolytic; Antipyrine; DNA; Drug-Related Side Effects and Adverse Reactions; Europe; Glucose | 1967 |
The clinical importance of pharmacogenetics.
Topics: Adult; Aged; Child, Preschool; Chromosome Aberrations; Chromosome Disorders; Congenital Abnormalitie | 1969 |